U.S. Malabsorption Syndrome Market Size, Share & Forecast 2026–2032

ID: MR-11778 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Malabsorption Syndrome Market
  • ✓Market Size 2024: USD 2.46 billion
  • ✓Market Size 2032: USD 3.90 billion
  • ✓CAGR: 5.9%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Generic Enzyme Formulary Squeeze: Viatris generic pancrelipase is displacing branded Creon on Medicare Part D formularies, forcing AbbVie to defend share through copay assistance. Specialty pharmacies capture most enzyme dispensing, shifting leverage away from retail chains. Players lacking payer contracts will lose volume regardless of quality.
FINDING 02
Medical Food Reimbursement Gap: The assumption that oral nutrition supplements will drive malabsorption revenue is wrong. Medical food reimbursement for Abbott and Nestlé Health Science remains out-of-pocket, and commercial plans are tightening coverage. Winners will convert nutrition products into prescription-covered therapies.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Payer Contracts Now: Enzyme and nutrition suppliers should lock Part D and commercial formulary positions before the 2026 plan-year bid cycle closes. Act within two quarters, because contract terms set volume for three years. Prioritize specialty pharmacy partnerships to capture dispensing share.

Competitive Overview of Malabsorption Care in the U.S.

The U.S. malabsorption care market is moderately fragmented across three product pools: prescription pancrelipase, medical foods and enteral formulas, and parenteral nutrition for severe cases. AbbVie's Creon and Viatris's generic pancrelipase hold the largest prescription share, while Nestlé Health Science, Abbott Laboratories, and Danone Nutricia dominate oral and enteral nutrition. Multinational firms control the high-margin nutrition and infusion segments, whereas domestic specialty pharmacies and small generic manufacturers compete on distribution reach and price. The top five players hold roughly 60 percent of revenue, so concentration is high at the product level but lower across the full care pathway.

Competitive advantage in the United States depends less on clinical efficacy than on reimbursement access and channel control. Payer formularies, Medicare Part D rules, and state Medicaid prior authorization requirements determine which enzyme and nutrition products reach patients. Firms with dedicated market access teams and pharmacy benefit manager contracts consistently outperform those relying on physician detailing alone. Domestic specialty pharmacy networks now hold substantial bargaining leverage, and foreign manufacturers must navigate that leverage through distribution partnerships to achieve scale.

Demand Drivers Shaping Malabsorption Care in the U.S.

Rising diagnosis rates for celiac disease, chronic pancreatitis, and cystic fibrosis are expanding the eligible patient base across American health systems. Broader adoption of fecal elastase testing and expanded celiac serology screening is pushing more patients into treatment pathways earlier. Abbott and Nestlé Health Science benefit most because their oral nutrition portfolios serve both pediatric and adult populations across these conditions. Viatris gains from generic enzyme volume as clinicians prescribe lower-cost alternatives to newly diagnosed patients, and pediatric gastroenterology referral growth in hospital networks concentrates prescribing among established specialists who reward manufacturers with strong clinical education programs.

An aging population drives post-surgical and chronic malabsorption linked to bariatric procedures and gastrointestinal resections. Bariatric surgical volumes, which exceed roughly 250,000 procedures annually in the United States, create recurring demand for micronutrient supplementation and enteral formulas. Danone Nutricia and Mead Johnson Nutrition compete for this patient group through hospital discharge programs and dietitian referral networks. Medicare Advantage plan expansion also shifts coverage toward plans that bundle nutrition benefits, favoring multinationals with integrated payer relationships over standalone generic suppliers.

Competitive Restraints and Market Challenges

Generic pancrelipase has compressed brand pricing, and Viatris's market entry has forced AbbVie into rebate-heavy contracting that lowers net revenue per prescription. Price competition in oral nutrition is equally intense, as retail private-label formulas undercut branded medical foods by a substantial margin. Smaller players without procurement scale struggle to match these price points across hospital and retail channels. Regulatory compliance costs from FDA oversight of medical food labeling and claims add further burden, particularly for firms without dedicated regulatory affairs teams capable of managing multi-state submissions.

Talent availability constrains competition in specialized clinical nutrition. Registered dietitians with pediatric enteral expertise are scarce in rural hospital systems, limiting how quickly manufacturers can expand home enteral programs. Infrastructure gaps in cold-chain distribution for enzyme and parenteral supplies raise logistics costs, favoring large distributors such as Baxter and B. Braun that operate dedicated home infusion networks. Prior authorization delays lasting several weeks also reduce conversion rates for new entrants attempting to win patients from incumbent brands.

Growth Opportunities for Market Players

Home enteral nutrition represents the clearest growth channel, as payers increasingly favor home care over extended hospital stays for stable malabsorption patients. Nestlé Health Science and Abbott are expanding direct-to-patient delivery programs, while Baxter and B. Braun are building home infusion networks that reduce readmission costs. Players that bundle nutrition products with remote monitoring and telehealth dietitian support can capture recurring revenue well beyond the initial product sale, particularly in Medicare and Medicaid populations.

Specialty and rare-disease therapies offer a second opening for innovators. Takeda's Gattex, approved for short bowel syndrome, demonstrated that orphan-designated injectables can command premium pricing in severe malabsorption cases. Companies developing GLP-2 analogues, microbiome-based therapies, or precision enzyme formulations can target patients who fail standard pancrelipase therapy. Orphan drug exclusivity provides seven years of U.S. market protection, rewarding first movers willing to fund clinical trials in narrow indications with high unmet need.

Market at a Glance

MetricValue
Market Size 2024USD 2.46 billion
Market Size 2032USD 3.90 billion
Growth Rate (CAGR)5.9%
Most Critical Decision FactorSecuring payer formulary access and specialty pharmacy distribution agreements
Largest RegionSouth Region
Competitive StructureModerately fragmented; top five hold about 60% share

Leading Market Participants

  • AbbVie
  • Viatris
  • Nestlé Health Science
  • Abbott Laboratories
  • Danone Nutricia
  • Mead Johnson Nutrition
  • Fresenius Kabi
  • Baxter International
  • Takeda
  • B. Braun Medical

Regulatory and Policy Environment

The FDA regulates pancrelipase as a drug under NDA and ANDA pathways, following its 2010 enforcement action that removed unapproved porcine enzyme products from the market. Medical foods fall under 21 CFR 101.9 labeling rules, while the Orphan Drug Act governs rare-indication therapies such as Gattex. These pathways create barriers that favor firms with established ANDA portfolios, since existing generic approvals give incumbents first-filer advantages over new entrants seeking pancrelipase market access.

The Inflation Reduction Act's Medicare drug price negotiation and Part D redesign shift financial risk onto manufacturers, reshaping how brands contract with payers. The Centers for Medicare and Medicaid Services administers Part D and Medicaid rules, while the Health Resources and Services Administration oversees the 340B Drug Pricing Program, which affects safety-net clinic purchasing. The Federal Trade Commission and state pharmacy boards scrutinize pharmacy benefit manager practices, directly influencing how specialty pharmacy networks compete for enzyme and nutrition volume.

Competitive Outlook for Malabsorption Care in the U.S.

By 2032 the competitive structure will shift from product-led to channel-led competition, as specialty pharmacies and home infusion providers capture a larger share of margin. Generic penetration in pancrelipase will rise further, compressing brand share for AbbVie and accelerating price-based rebate contracting. Multinational nutrition companies will consolidate medical food portfolios through acquisitions of smaller domestic brands, widening their advantage in procurement and clinical education.

Domestic specialty networks and integrated home-care providers will hold stronger bargaining positions with payers by 2032. Winners will combine payer contracting depth, dietitian-led patient support, and rare-disease pipelines into a single offering. Companies relying solely on product margin in pancrelipase or oral nutrition will face sustained consolidation pressure throughout the forecast period.

Frequently Asked Questions

The top five players, led by AbbVie, Viatris, and Nestlé Health Science, hold roughly 60 percent of revenue. Their advantage comes from prescription enzyme franchises and established nutrition portfolios.
Domestic specialty pharmacies and home care providers compete on distribution reach and payer relationships rather than scale. Their local networks give them bargaining leverage that foreign manufacturers must access through partnerships.
Formulary placement and reimbursement access determine which products reach patients. Firms with dedicated market access teams and pharmacy benefit manager contracts consistently outperform competitors.
Viatris's generic pancrelipase has forced AbbVie into rebate-heavy contracts that reduce net revenue per prescription. Price pressure is equally strong in oral nutrition, where private-label formulas undercut branded medical foods.
Companies that combine payer contracting, home enteral and infusion delivery, and rare-disease pipelines are best positioned. Nestlé Health Science, Abbott, Baxter, and Takeda each hold elements of this model.

Market Segmentation

By Product Type
  • Pancrelipase Enzyme Replacement
  • Oral Nutrition Supplements
  • Enteral Formulas
  • Parenteral Nutrition
  • Medical Foods
By End User
  • Hospitals
  • Specialty Clinics
  • Home Care Settings
  • Ambulatory Surgical Centers
  • Long-Term Care Facilities
By Distribution Channel
  • Retail Pharmacies
  • Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Home Infusion Providers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Malabsorption Syndrome - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Pancrelipase Enzyme Replacement
4.2 Oral Nutrition Supplements
4.3 Enteral Formulas
4.4 Parenteral Nutrition
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Specialty Clinics
5.3 Home Care Settings
5.4 Ambulatory Surgical Centers
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Retail Pharmacies
6.2 Specialty Pharmacies
6.3 Hospital Pharmacies
6.4 Online Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 AbbVie
7.2.2 Viatris
7.2.3 Nestlé Health Science
7.2.4 Abbott Laboratories
7.2.5 Danone Nutricia
7.2.6 Mead Johnson Nutrition
7.2.7 Fresenius Kabi
7.2.8 Baxter International
7.2.9 Takeda
7.2.10 B. Braun Medical
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.